MedTrace Logo

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

NCT07072234 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-29

No results posted yet for this study

Summary

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Conditions

  • Clear Cell Carcinoma
  • Phase 1
  • Growth Factor

Interventions

DRUG

Lymphodepleting chemotherapy

Given by IV

DRUG

Dexamethasone

Given PO

DRUG

Fludarabine

Given by IV

DRUG

Cyclophosphamate

Given by IV

DRUG

TGFBR-2 KO CD70 CAR NK

Given by IV

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Andrew C Johns, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-25
Primary Completion
2028-02-01
Completion
2030-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07072234 on ClinicalTrials.gov